Neubase Therapeuticsincis A Preclinical Stage Biopharmaceutical Company Based In Pittsburghpennsylvaniafounded In 2009The Company Focuses On Developing Innovative Therapies For Rare Genetic Diseases And Cancers Caused By Mutant Genesneubase Is Recognized For Its Proprietary Modular Peptide Nucleic Acid Antisense Oligopatrolplatformwhich Aims To Provide Targeted Treatments For Genetic Disorders The Primary Service Offered By Neubase Is The Development Of Next Generation Antisense Oligonucleotideasotherapiesthe Product Pipeline Includes Nt0100 For Huntington S Diseasent0200 For Myotonic Dystrophy Type 1And Nt0300 Targeting Cancers Associated With The Mutated Kras Genethese Therapies Leverage The Patrol Platform To Potentially Offer New Treatment Options For Conditions With Limited Existing Therapies
No conferences found for this company.
| Company Name | Neubase Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
